Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Structure-activity relationships within a series of caspase inhibitors: effect of leaving group modifications.
Ullman BR, Aja T, Deckwerth TL, Diaz JL, Herrmann J, Kalish VJ, Karanewsky DS, Meduna SP, Nalley K, Robinson ED, Roggo SP, Sayers RO, Schmitz A, Ternansky RJ, Tomaselli KJ, Wu JC. Ullman BR, et al. Among authors: kalish vj. Bioorg Med Chem Lett. 2003 Oct 20;13(20):3623-6. doi: 10.1016/s0960-894x(03)00755-8. Bioorg Med Chem Lett. 2003. PMID: 14505683
Acyl dipeptides as reversible caspase inhibitors. Part 2: further optimization.
Linton SD, Karanewsky DS, Ternansky RJ, Chen N, Guo X, Jahangiri KG, Kalish VJ, Meduna SP, Robinson ED, Ullman BR, Wu JC, Pham B, Kodandapani L, Smidt R, Diaz JL, Fritz LC, von Krosigk U, Roggo S, Schmitz A, Tomaselli KJ. Linton SD, et al. Among authors: kalish vj. Bioorg Med Chem Lett. 2002 Oct 21;12(20):2973-5. doi: 10.1016/s0960-894x(02)00630-3. Bioorg Med Chem Lett. 2002. PMID: 12270186
Structure-activity relationships within a series of caspase inhibitors. Part 2: Heterocyclic warheads.
Ullman BR, Aja T, Chen N, Diaz JL, Gu X, Herrmann J, Kalish VJ, Karanewsky DS, Kodandapani L, Krebs JJ, Linton SD, Meduna SP, Nalley K, Robinson ED, Roggo SP, Sayers RO, Schmitz A, Ternansky RJ, Tomaselli KJ, Wu JC. Ullman BR, et al. Among authors: kalish vj. Bioorg Med Chem Lett. 2005 Aug 1;15(15):3632-6. doi: 10.1016/j.bmcl.2005.05.036. Bioorg Med Chem Lett. 2005. PMID: 15964758
First-in-class pan caspase inhibitor developed for the treatment of liver disease.
Linton SD, Aja T, Armstrong RA, Bai X, Chen LS, Chen N, Ching B, Contreras P, Diaz JL, Fisher CD, Fritz LC, Gladstone P, Groessl T, Gu X, Herrmann J, Hirakawa BP, Hoglen NC, Jahangiri KG, Kalish VJ, Karanewsky DS, Kodandapani L, Krebs J, McQuiston J, Meduna SP, Nalley K, Robinson ED, Sayers RO, Sebring K, Spada AP, Ternansky RJ, Tomaselli KJ, Ullman BR, Valentino KL, Weeks S, Winn D, Wu JC, Yeo P, Zhang CZ. Linton SD, et al. Among authors: kalish vj. J Med Chem. 2005 Nov 3;48(22):6779-82. doi: 10.1021/jm050307e. J Med Chem. 2005. PMID: 16250635
Structure-based design of novel, urea-containing FKBP12 inhibitors.
Dragovich PS, Barker JE, French J, Imbacuan M, Kalish VJ, Kissinger CR, Knighton DR, Lewis CT, Moomaw EW, Parge HE, Pelletier LA, Prins TJ, Showalter RE, Tatlock JH, Tucker KD, Villafranca JE. Dragovich PS, et al. Among authors: kalish vj. J Med Chem. 1996 Apr 26;39(9):1872-84. doi: 10.1021/jm950798a. J Med Chem. 1996. PMID: 8627611
Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.
Kaldor SW, Kalish VJ, Davies JF 2nd, Shetty BV, Fritz JE, Appelt K, Burgess JA, Campanale KM, Chirgadze NY, Clawson DK, Dressman BA, Hatch SD, Khalil DA, Kosa MB, Lubbehusen PP, Muesing MA, Patick AK, Reich SH, Su KS, Tatlock JH. Kaldor SW, et al. Among authors: kalish vj. J Med Chem. 1997 Nov 21;40(24):3979-85. doi: 10.1021/jm9704098. J Med Chem. 1997. PMID: 9397180
17 results